Ayurveda Interventions in Parkinsons disease

Evaluation of Clinical effectiveness of Ayurveda Multi-Modal Treatment(CCRAS-Park) in Parkinsons disease: an exploratory Pilot Trial - CCRAS PARK

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/01/102344

Enrollment

Registered

2026-01-28

Start date

Unknown

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G20- Parkinsons disease

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Participants who are diagnosed with PD of greater than 2year duration and are non-ambulatory. Patients those who are relatively stable during the study period and remained stable on medication in the last 2 months. Willing to comply and provide written informed consent, for intervention treatment Participants receiving dopaminergic medications will be asked to continue the same up to completion of study (6 months)

Exclusion criteria

Exclusion criteria: Prior diagnosis of dementia or mild cognitive impairment on screening MOCA 24, other psychiatric symptoms History of co morbid neurologic disorders or major cardiovascular conditions, history of deep brain stimulation or other brain surgery, neurogenic orthostatic hypotension, clinically diagnosed chronic respiratory illness, liver disease, renal disease, uncontrolled hypertension, pregnancy Any other condition that the investigator believes makes him or her unsuitable for participation in this study

Design outcomes

Primary

Measure	Time frame
UPDRS scale, Freezing of gait questionnaire - I(FOG-Q), Falls efficacy scale, gait evaluation parameters like Velocity (cm/sec), Average step length (cm), Average stance time (s)Timepoint: base line, day 30, day 60, day 90, day 120, day 180	—

Secondary

Measure	Time frame
To evaluate changes in cognitive outcome parameters using Parkinson s Disease Cognitive Functional Rating Scale (PD-CFRS) and Montreal Cognitive Assessment Scale (MoCA)Timepoint: Day 1,30th day, 60th day, 90th day,120th day and 180th day;Proportion of participants demonstrating a reduction in the dose of dopaminergic medication or prevention of dose escalation, assessed on the 90th day and 180th day, compared to baseline medication status.Timepoint: 90th day, 180th day;To assess the adverse events reported by CCRAS Park protocolTimepoint: 1-30th day, 60th day, 90th day, 120th day,180th day.;Tolerability of CCRAS-park protocol measured from treatment adherence table in case record formTimepoint: Day 30, 60, 90, 120 and 180.	—

Measure

Time frame

To evaluate changes in cognitive outcome parameters using Parkinson s Disease Cognitive Functional Rating Scale (PD-CFRS) and Montreal Cognitive Assessment Scale (MoCA)Timepoint: Day 1,30th day, 60th day, 90th day,120th day and 180th day;Proportion of participants demonstrating a reduction in the dose of dopaminergic medication or prevention of dose escalation, assessed on the 90th day and 180th day, compared to baseline medication status.Timepoint: 90th day, 180th day;To assess the adverse events reported by CCRAS Park protocolTimepoint: 1-30th day, 60th day, 90th day, 120th day,180th day.;Tolerability of CCRAS-park protocol measured from treatment adherence table in case record formTimepoint: Day 30, 60, 90, 120 and 180.

—

Countries

India

Contacts

Public ContactDr Devi R Nair

National Ayurveda Research Institute for Panchakarma Cheruthuruthy

drdevinair87@gmail.com09074298620

Outcome results